Vertex Pharmaceuticals Incorporated (VRTX)
Automate Your Wheel Strategy on VRTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VRTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VRTX
- Rev/Share 45.8658
- Book/Share 67.7574
- PB 4.3302
- Debt/Equity 0.0738
- CurrentRatio 2.3618
- ROIC 0.1618
- MktCap 108089527572.0
- FreeCF/Share 13.0563
- PFCF 32.3893
- PE 29.2941
- Debt/Assets 0.0738
- DivYield 0
- ROE 0.1962
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | VRTX | Leerink Partners | Market Perform | Outperform | -- | $456 | Sept. 25, 2025 |
| Initiation | VRTX | Raymond James | -- | Market Perform | -- | -- | Sept. 3, 2025 |
| Upgrade | VRTX | Wells Fargo | Equal Weight | Overweight | -- | $460 | Aug. 6, 2025 |
| Downgrade | VRTX | Wolfe Research | Outperform | Peer Perform | -- | -- | May 7, 2025 |
| Downgrade | VRTX | Leerink Partners | Outperform | Market Perform | -- | $503 | May 6, 2025 |
| Resumed | VRTX | Cantor Fitzgerald | -- | Overweight | -- | $535 | April 22, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | $408 | $424 | Feb. 12, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | -- | -- | Feb. 11, 2025 |
| Downgrade | VRTX | Wells Fargo | Overweight | Equal Weight | -- | $460 | Jan. 30, 2025 |
| Reiterated | VRTX | H.C. Wainwright | -- | Buy | $600 | $535 | Dec. 20, 2024 |
News
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated ( VRTX ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Reshma Kewalramani - CEO, President & Director Conference Call Participants Dina Elmonshed Presentation Dina Elmonshed Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge.
Read More
Committee stocks on the move: Uber and Vertex Pharma
Published: November 04, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee discuss some of their stocks on the move today.
Read More
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
Read More
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Published: November 03, 2025 by: Benzinga
Sentiment: Positive
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release earnings results for the first quarter, after the closing bell on Monday, Nov. 3.
Read More
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.
Read More
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Read More
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
Published: October 17, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential.
Read More
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
Published: October 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $408.85, representing a +1.15% change from its previous close.
Read More
Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Positive
Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three key drugs, Trikafta, Kaftrio, and Alyftrek, which are part of the CF portfolio, reached about $2.71 billion in the second quarter of 2025, up 10.6% year-on-year. On the positive side, Vertex's operating income margin, which was 38.9% for the three months ended June 30, 2025, is higher than that of its competitors, including Pfizer and Sarepta.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Vertex Plunges Around 24% in Six Months: How to Play the Stock
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
Published: September 11, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year's Lasker~DeBakey Clinical Medical Research Award for his role “in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIKAFTA®, that has helped countless people with this genetic disease.” Dr. Negulescu is one of three awardees, alongside Jesús (.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Reshma Kewalramani - CEO, President & Director Duncan J. McKechnie - Chief Commercial Officer, Head of North America Commercial & Executive VP Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 11:00 AM EDT Company Participants Susie Lisa - Senior Vice President of Investor Relations Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Great. Thank you very much for joining us today.
Read More
Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Undercovered Dozen: BrightSpire Capital, Vertex Pharmaceuticals, Adobe And More
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Positive
This week's Undercovered Dozen spotlights 12 lesser-known stocks and ETFs, offering unique investment opportunities across gold, biotech, income, and tech sectors. B2Gold and Vertex Pharmaceuticals stand out as strong buys, driven by robust fundamentals, sector leadership, and clear growth catalysts for 2025 and beyond. Caution is urged on popular income-focused ETFs like SPYI and ULTY, as structural flaws and capped upside may limit long-term wealth compounding.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet
Published: August 12, 2025 by: Seeking Alpha
Sentiment: Negative
A 20% drop in Vertex Pharmaceuticals' stock price since I wrote last month was the impetus to make a re-assessment. But the rating has remained unchanged at Hold. This is despite significantly improved Q2 2025 results, seen in both revenue and non-GAAP earnings' growth, with revenues supported by the likes of Alyftrek and Journavx,. However, an unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led to a price plunge.
Read More
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results
Published: August 05, 2025 by: Benzinga
Sentiment: Neutral
Vertex Pharmaceuticals Inc VRTX reported better-than-expected earnings for the second quarter after the market close on Monday.
Read More
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.
Read More
Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug
Published: August 05, 2025 by: Investopedia
Sentiment: Negative
Shares of Vertex Pharmaceuticals (VRTX) sank 15% Tuesday, a day after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.
Read More
Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key Metrics
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Vertex (VRTX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
About Vertex Pharmaceuticals Incorporated (VRTX)
- IPO Date 1991-07-24
- Website https://www.vrtx.com
- Industry Biotechnology
- CEO Reshma Kewalramani FASN,
- Employees 6100